Association of Recent and Long-Term Supplement Intakes With Laboratory Indices in Patients With COVID-19 in Tehran, Iran, During 2020

Rezvan Hashemi1†, Mohsen Montazer2†, Zahra Salehi2 and Leila Azadbakht2,3,4*

1 Department of Geriatric Medicine, Ziaeian Hospital, Tehran University of Medical Sciences, Tehran, Iran, 2 Department of Community Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences, Tehran, Iran, 3 Diabetes Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran, * Department of Community Nutrition, School of Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, Iran

Background: Although previous studies observed the relationship between individual dietary supplements and enhancing body resistance against viruses, few studies have been conducted regarding the role of different supplements in treatment of COVID-19. This article aims to determine the association of recent and long-term supplement consumption on the biochemical indices and impatient duration among patients with COVID-19.

Methods: In this cross-sectional study on 300 adult men and women with COVID-19, recent and long-term supplement intakes were investigated by using a questionnaire. In addition, lifestyle was also assessed in aspects of fruits and vegetable consumption, physical activity, sleeping duration, fluid intake, and smoking status. Furthermore, the laboratory and paraclinical parameters were obtained from medical records. The relationship between supplement intake with the length of hospitalization and clinical laboratory tests was investigated by one-way analysis of variance (ANOVA).

Results: Those patients with supplement intake in the last 2 months had a significantly lower amount of blood urea nitrogen (BUN) (31.31 ± 13.87 vs. 37.57 ± 19.77 mg/dL, P: 0.002) and higher serum 25(OH)D (28.13 ± 14.09 vs. 23.81 ± 13.55 ng/mL, P: 0.03). Subjects with long-term supplement intake had a significantly lower invasive oxygen support (0.00 vs 5.10 %, P: 0.05), lactate dehydrogenase (LDH) (498.11 ± 221.43 vs. 576.21 ± 239.84 U/L, P: 0.02), fewer days of fever (0.49 ± 3.54 vs. 2.64 ± 9.21, P: 0.02), and higher serum 25(OH)D (31.03 ± 13.20 vs. 22.29 ± 13.42 ng/mL, P < 0.001). The length of hospital stay was practically the same between groups who received and did not receive supplementation during the 2 months prior to hospitalization (6.36 ± 3.32 vs. 6.71 ± 4.33 days, P: 0.004). Similarly, people who took supplements during the past year had practically similar hospitalization lengths (6.29 ± 4.13 vs. 6.74 ± 3.55 days, P: 0.004).
Conclusion: In conclusion, although practically the length of hospital stay was the same in both groups of supplement consumers and others, immune-boosting supplements were associated with improved several laboratory indices. However, due to the cross-sectional nature of our study, further longitudinal studies seem to be essential.

Keywords: supplement, COVID-19, BUN, ICU, general ward, creatinine, CRP

INTRODUCTION

The new variation of coronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), which triggers COVID-19, is undoubtedly the foremost dangerous coronavirus with the greatest morbidity and death rate. Human society experienced the most important acute health trouble due to the coronavirus pandemic in recent year (1). The crude mortality ratio is 1.63% based on Worldometer by January 21, 2022 (2), which can vary in different countries depending on age and the presence of comorbidities (1).

As of January 21, 2022, 9,807,128,664 doses of the COVID-19 vaccine have been administered worldwide, according to covidvax; however, maintaining social distancing and carrying face masks are recommended in public spaces to avoid the transmission of COVID-19 (3). Furthermore, lifestyle factors, including dietary intake, exercise, smoking, alcohol intake, screen time, and sleep, may also additionally have a crucial influence on COVID-19 vulnerability (4). Hence, many researchers highlighted the importance of taking suitable dietary interventions and nutritional supplements to boost our immune systems. The relationship between taking protein, omega-3, vitamin A, B complex, C, D, E, minerals like zinc, selenium, iron, copper, and magnesium supplements and improving the immune system has been investigated (5–16). Previous studies have also investigated the effects of glycosphosphopetalic AM3 on respiratory diseases (17, 18). Furthermore, a review study has discussed the potential prophylactic and therapeutic benefits of glycosphosphopetalic AM3 on COVID-19 (19). Vitamin D, lactoferrin, and selenium supplementation have possibly desirable effects on COVID-19 prevention (11, 20–25). It is recently reported that D3 intake for a few weeks at 10 000 IU/d followed by 5,000 IU/d to reach the minimum of 150 nmol/L for 25(OH)D serum is a prophylactic measure to COVID-19 for high-risk people (8). The researchers recently reported vitamin D, zinc, omega-3, vitamin C, selenium, magnesium, lactoferrin, L-glutamine, gut microbiota, nigella sativa, and propolis supplementation could be considered as possible COVID-19 treatments (15, 22, 25–33). Early dietary supplementation in suspicious COVID-19 cases can contribute to better treatment results, and good nutritional status is essential prior to the other medical measures (33).

The necessity of immune-boosting supplementation is one of the most common ambiguities during the COVID-19 pandemic. Furthermore, in patients with COVID-19, possible differences in length of hospital stay and biochemical parameters in people who took the supplements with others are yet to be determined. In general, the benefits of taking immune-boosting supplements during the COVID-19 pandemic are not completely conclusive. Previous studies have observed relationships between appropriate nutritional status and enhancing body resistance against viruses (33–35). However, the information about supplementation as a preventive and treatment measure for COVID-19 remains controversial. Although there are reports on patients with COVID-19 nutritional supplement effects, there is no study on multi-dietary supplement's role in the prevention and treatment of COVID-19 simultaneously. This article aims to determine the association of recent and long-term supplement consumption before disease incidence on the biochemical indices and impatient duration among infected patients to COVID-19.

MATERIALS AND METHODS

Study Design and Population

The main aim of this cross-sectional study was to investigate the association of recent and long-term supplement intakes with laboratory indices and length of hospital stay in hospitalized patients with COVID-19. Participants were recruited from patients with COVID-19 hospitalized in Ziaeian hospital affiliated with Tehran University of Medical Sciences. The data collection process was performed from March 24, 2020, to November 20, 2020. This study was performed on 300 adults aged 18 years and older admitted to Ziaeian Hospital who were randomly selected. Subjects were confirmed patients with COVID-19 diagnosed by the general practitioner (GP) regarding laboratory results, lungs CT scan, and clinical symptoms simultaneously. Consumption of dietary supplements in the last 2 months and the past year was classified into recent and long-term supplement intakes, respectively. Supplement intake modulating the immune system function, such as A, C, D, E, and B vitamins, zinc, selenium, iron, omega-3, and protein, as well as probiotics, was studied. Written informed consent was obtained from all participants. Inclusion criteria were as follows: no pregnancy, no lactation, and no serious condition, such as dementia, history of a large stroke, and active cancer within 5 years. Patients with non-communicable diseases, such as diabetes, hypertension, hyperlipidemia, hypothyroid, kidney disease, and fatty liver, were included. This study was approved by the ethical committee of Tehran University of Medical Sciences with the ethics code IR.TUMS.VCR.REC.1399.036 and grant number 99-1-212-47266.

Assessment of Anthropometric and Obesity Characteristics

Anthropometric parameters, such as weight, height, and body mass index of patients, were measured at admission. Weight
was measured with light clothing and using a digital scale with an accuracy of 100 grams, and height was also obtained using a stadiometer with an accuracy of 0.1 cm after removing the shoes. To reduce possible errors, all these measurements were performed by a healthcare staff. Using a demographic questionnaire, patient sudden and severe weight changes in the last month were assessed. Moreover, to evaluate weight changes during hospitalization, subjects’ weight was measured at the time of discharge. Finally, body mass index was computed by dividing weight (kg) to the square of height (m²).

Assessment of Usual Dietary and Supplement Intake
Daily energy intake, and macro- and micronutrients of the subjects were obtained using 24-h recall based on the number of hospitalization days during hospital stay. Using USDA modified food composition table for Iranian foods, the daily macro- and micronutrient intake of each patient was calculated (36). Patients were evaluated regarding following a special diet before the onset of the disease, servings of fruit consumption per day during the past year, number of daily main meals received, type and amount of bread, meat, dairy, and oil consumed, and the frequency of fast-food consumption. Moreover, the amount of main meals and snacks consumed during hospitalization in comparison with the amount consumed before the onset of the disease was obtained using questionnaire. In addition, fluid intake habits regarding the frequency of carbonated beverages consumption and daily water intake were assessed based on questionnaire data. Finally, to assess the nutrition status of each participant, an overall nutrition score was applied. We obtained the overall nutrition score for each participant by summing the scores of the type of meat consumed, the type of bread consumed, the amount of dairy consumed, the amount consumed of fruits and vegetables, and the consumption of sweetened carbonated beverages. The points allocated were as follows: consumption of red meat 0, chicken 1, fish 2, consumption of <1 glass of dairy 0, 1 glass of dairy 1, 2 glass of dairy 2, 3 glass of dairy 3, >3 glass of dairy 4, consumption of carbonated beverages 0 and non-consumption 1, consumption of white bread 0 and whole wheat bread 1, consumption of 1 unit of fruits 1, 2 units of fruits 2, 3 units of fruits 3 and consumption of <1 unit of vegetables 0, 1 unit of vegetables 1, 2 units of vegetables 2, 3 units of vegetables 3, and >3 units of vegetables 4 points were assigned. To evaluate the recent intake of supplements, we considered taking supplements during 2 months before hospitalization. We also obtained supplement intake during 1 year before admission to assess long-term supplementation. Long-term (over 1 year) and more recently (over the last 2 months) vitamin, mineral, probiotic, omega-3s, and protein supplement intake have been evaluated, and subjects have been asked to list their possible consumed supplements and state the received dose. Using supplement intake questionnaire, received supplements involved in the immune system function, such as A, C, D, E, and B vitamins, zinc, selenium, iron, omega-3, and protein, as well as probiotics, were obtained.

Assessment of Comorbidities and Medications
Patient current comorbidities, such as diabetes, hypothyroid, asthma, arthroses, Alzheimer's disease, rheumatoid arthritis, chronic obstructive pulmonary disease, end-stage renal disease, Parkinson's, kidney failure, hepatitis B, meningitis, human immunodeficiency virus, cerebral vascular accident, chronic kidney disease, mental disease, obesity, and immune system deficiency, were obtained using medical records. In addition, based on medical record data, cardiovascular disease risk factors, including hypertension, hyperlipidemia, ischemic heart disease (IHD), deep vein thrombosis (DVT), congenital heart defects (CHD), coronary artery disease (CAD), and congestive heart failure (CHF), were assessed. Likewise, using questionnaire, a history of heart valve replacement, dialysis, coronary artery bypass graft surgery (CABG), liver surgery, chemotherapy, and various types of transplants were obtained. Furthermore, received medications during the hospitalization period with emphasis on immune system suppressors, such as corticosteroids and their dosage, were extracted from the questionnaire. Patients were also evaluated in terms of antiviral drugs azithromycin, heparin, oseltamivir, Kaletra, ribavirin, favipiravir, remdesivir, azatanavir, and ivermectin consumption based on medical record data. In addition to current diseases and drugs, a history of diseases and drugs was also obtained regarding medical records. The history of lipid-lowering, anticoagulant, psychiatry, statin, angiotensin-converting enzyme inhibitors (ACEIs), and angiotensin II receptor blocker (ARB) drugs were assessed using the questionnaire. The possible underlying disease, as well as the severity of the disease, was stated in the questionnaire based on the paraclinical findings in the medical records.

Assessment of Clinical and Paraclinical Findings
Laboratory clinical tests were performed at the time of hospital admission using conventional methods, such as routine blood tests, cardiometabolic factors, renal function, liver enzymes, coagulation factors, and inflammation profile. The serum levels of important laboratory and paraclinical parameters, including blood urea nitrogen (BUN), creatinine, albumin, ferritin, 25(OH) vitamin D, C-reactive protein (CRP), d-dimer, and hemoglobin, were extracted using a questionnaire. In addition, according to medical records, other paraclinical findings in terms of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALKP) hepatic enzymes, electrolytes, creatine phosphokinase (CPK), lactate dehydrogenase (LDH), fasting blood sugar (FBS), HCO3, pH, partial pressure of oxygen (PO2), partial pressure of carbon dioxide (PCO2), and troponin serum levels were obtained. To measure CRP, troponin, ferritin, sodium, potassium, albumin, AST, ALT, LDH, creatinine, and urea, Abbott’s Alinity Systems (Abbott, Chicago, IL, USA) were applied on plasma samples added with lithium heparin (Becton Dickinson, Franklin Lakes, NJ, USA). FBS levels were determined using the glucose oxidase-phenol 4-aminoantipyrine peroxidase (GOD-PAP) colorimetric method. Routine blood factors, such as white blood cell (WBC),
red blood cell (RBC) and platelet count, neutrophils, lymphocytes and HCT percentage, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), and erythrocyte sedimentation rate (ESR), were obtained from anticoagulated blood samples with ethylenediaminetetraacetic acid tripotassium (K3 EDTA; Becton Dickinson, Franklin Lakes, NJ, USA) using Sysmex XN hematology analyzer and reagents (Sysmex Corporation, Kobe, Japan). Partial thromboplastin time (PTT), partial prothrombin time (PT), international normalized ratio (INR), and D-dimer were measured by benchtop analyzer STA compact Max 3 (Stago, Asnières-sur-Seine, France) and reagents on serum evacuated to 3.2% sodium citrate coagulation tubes (Becton Dickinson, Franklin Lakes, NJ, USA). The patient's symptoms, such as general pain, headache, cough, sore throat, joint pain, respiratory problems, anorexia, runny nose, lethargy, diarrhea, and vomiting, were documented in a questionnaire based on the evidence in the patient medical records.

### Assessment of Other Variables

Related data on sociodemographic variables, including age, sex, education, occupation, residency, family status, and marital status, were extracted from the demographic questionnaire. Female participants were assessed in aspects of the physiologic condition, such as pregnancy, lactation status, number of deliveries, and menopausal status, additionally. Lifestyle-related variables, including smoking status, current and past history of alcohol consumption and drug abuse, daily physical activity, facing stressful events in the last 6 months, and sleep duration changes, were obtained using a questionnaire. Finally, using questionnaire, the method of diagnosis of COVID-19 disease, the extent of contact with COVID-19 patients before infection, inpatient or non-hospital treatment, place of hospitalization, duration of hospitalization in addition to general condition at the time of discharge from the hospital were assessed.

### Statistical Analysis

Participants were categorized regarding recent and long-term supplement consumption. We applied one-way ANOVA and chi-square tests for continuous and categorical variables, respectively, to compare sociodemographic characteristics across different supplement intake categories. The relationship between more recent and long-term supplement intakes with the length of hospitalization was assessed using one-way ANOVA. Similarly, the association of recent and long-term supplementation with clinical laboratory tests was investigated by one-way ANOVA. By applying the chi-square test, recent and long-term supplement consumption relationships with the symptoms of disease (fever, cough, headache, runny nose, and sore throat) were examined. Moreover, the prevalence of various comorbidities and medications across different categories of supplement intake was assessed using the chi-square test. Potential confounders which were likely to affect the outcomes of our study were adjusted in three phases using ANCOVA. One of the factors that may affect the laboratory indices and duration of hospitalization is medication. We examined the interaction of drugs with supplements in such a way that in a separate model, we performed statistical adjustments. If the effect of the interaction of drugs with supplements was significant, then the effect would disappear. In model 1, variables of gender, age, history and the current onset of diseases, and history and current medications adjustment was presented in model 1 (Figure 1). Furthermore, in model 2, the P-values were controlled by body mass index, hemoglobin, and nutrition overall score, additionally, which were included as covariates (Figure 1). Finally, in model 3, multiple variable adjustments were performed and the existence of respiratory support, fever, blood oxygen level, partial pressure of carbon dioxide, albumin, 25(OH)D, and c-reactive protein serum levels were included as covariates, additionally.

### RESULTS

Out of 300 subjects in the present study, 164 and 138 patients had recent and long-term supplement intake, respectively. 54.7% of the participants were males and 45.3% were females with a mean age of 51.95 ± 15.34 years. Table 1 and Supplementary Table 1 represent the sociodemographic characteristics of patients with COVID-19 who were included in the present study. People who have been supplemented in the last 2 months were younger, slightly higher educated, obese, and more stressed than those who did not take the supplement recently. Similarly, people who received supplements in the past year were people with younger age, more percentage of women, slightly more traveling experience, more sleep-alteration, and more stressful events than those who did not receive the supplement. There was no significant difference in marital status, the number of family members, job classification and comorbidities except for obesity in the two groups of recent supplementation and non-recent supplementation. No significant difference was observed in marital status, number of family members, job classification and comorbidities except for immune deficiency and asthma across different long-term supplementation groups. Anthropometric and obesity characteristics of patients with COVID-19 across recent and long-term supplementation categories are presented in Table 2. In people who have recently taken supplements, more weight changes have been observed, approaching the marginal significance (P = 0.07). Similarly those subjects with recent supplement intake showed significantly more prevalence of obesity (P = 0.04). Supplementation in recent years has been associated with less weight change (P = 0.002). History of different diseases and diagnosis methods among patients with COVID-19 are presented in Supplementary Table 2. Dietary intake during hospitalization among patients with COVID-19 in different supplement categories intake has been provided in Supplementary Table 3. There was a significant difference in the amount of breakfast and dinner consumption of those who took the supplement recently and those who did not take the supplement recently (P =0.004, 0.04). The use of different drugs did not differ much between the two groups. No significant difference was found in terms of dietary intake...
and medication in those who took or did not take supplements in the past year. **Supplementary Table 4** illustrates the usual dietary intake among patients with COVID-19 in different supplement categories intake. There was a significant difference in the frequency of fast food consumption, consumption of lipid-lowering drugs and statins in those subjects with recent supplements compared to those who did not take supplements recently. Beverage and anticoagulants consumption was significantly different in those who did and did not receive supplementation in the past year ($P = 0.05, 0.01$). Biochemical indices in different supplement intake categories are provided in **Supplementary Table 5**. Alkaline phosphatase ($146.64 \pm 67.21$ vs. $176.96 \pm 143.10$ IU/L, $P = 0.03$) and MCV ($84.70 \pm 6.56$ vs. $86.39 \pm 5.19$ fl, $P = 0.02$) were significantly lower in the group that had taken the supplement in the last 2 months. Subjects with long-term supplement intake had significantly lower LDH ($498.11 \pm 221.43$ vs. $576.21 \pm 239.84$ U/L, $P = 0.02$), hematocrit ($39.46 \pm 6.03$ vs. $40.81 \pm 5.23$ %, $P = 0.04$) MCV ($84.47 \pm 5.35$ fl, $P = 0.008$), and significantly higher lymphocytes ($25.15 \pm 11.29$ vs. $21.93 \pm 10.90$ %, $P = 0.01$). Important parameters in different supplement categories are illustrated in **Table 3**. Recent supplementation was associated with lower BUN ($31.31 \pm 13.87$ vs. $37.57 \pm 19.77$ mg/dL, $P = 0.002$) and higher $25(OH)D$ serum levels ($28.13 \pm 14.09$ vs. $23.81 \pm 13.55$ ng/mL, $P = 0.03$). $25(OH)D$ serum level was significantly higher in those who had taken supplements in the past year ($31.03 \pm 13.20$ vs. $22.29 \pm 13.42$; $P < 0.001$). Clinical and para-clinical parameters have been provided in **Table 4**. Compared to those who have not taken supplements recently, no parameter was significantly different in the supplemented group. After performing multiple variable adjustments, those with recent ($0.70 \pm 4.41$ vs. $3.07 \pm 9.96$ days, $P < 0.001$) and long-term supplementation intake had fewer days of fever ($0.74 \pm 4.70$ vs. $2.80 \pm 9.46$ days, $P < 0.001$). Furthermore, recent ($91.83 \pm 10.03$ vs. $85.89 \pm 21.06$ %, $P < 0.001$) and long-term supplement consumption was associated with higher blood oxygen pressure after statistical adjustments ($91.50 \pm 11.20$ vs. $86.77 \pm 19.83$ %, $P < 0.001$).

The length of hospitalization after gender, age, history and the current onset of diseases and history and current medications adjustment are presented in model 1 (**Table 5** and **Figure 1**). The $P$-values were controlled by body mass index, hemoglobin and nutrition overall score, which were included as covariates additionally in model 2 (**Table 5** and **Figure 1**). In model 3, $P$-values were controlled by the existence of respiratory support, fever and blood oxygen level, partial pressure of carbon dioxide, albumin, $25(OH)D$, c-reactive protein serum levels, in addition to the above variables which were included as covariates. Although, those who recently supplemented had slightly fewer hospital stays, the length of hospitalization was practically the same ($6.36 \pm 3.22$ vs. $6.71 \pm 3.43$ days, $P = 0.004$). Similarly, People who took supplements in the past year also had similar hospitalization lengths ($6.29 \pm 4.13$ vs. $6.74 \pm 3.55$ days, $P = 0.004$) (**Table 5** and **Figure 1**).

**DISCUSSION**

In this cross-sectional study, we did not find a significant inverse relationship between supplementation in the last 2 months and...
| Sociodemographic characteristics of patients with COVID-19 according to recent, long-term, and during hospitalization intakes. |
|---------------------------------------------------------------|
| **Table 1**                                                   |
| **Total** | **Recent supplement intake** | **Yes** | **Long-term supplement intake** | **Yes** |
|-----------|-----------------------------|--------|-------------------------------|--------|
| Sample size, n | 300 (100%) | 138 (46%) | 162 (54%) | 162 (54%) | 138 (46%) |
| Age (years) | 51.95 ± 15.34 | 54.72 ± 15.28* | 49.59 ± 15.05 | 53.57 ± 15.37* | 50.04 ± 15.14 |
| Gender |               |        |                              |        |
| Men | 164 (54.7%) | 87 (63.1%)* | 77 (47.5%) | 101 (62.3%)* | 63 (45.6%) |
| Women | 136 (45.3%) | 51 (36.9%)* | 85 (52.5%) | 61 (37.7%)* | 75 (54.4%) |
| Number of family members | 3.36 ± 1.29 | 3.46 ± 1.47 | 3.29 ± 1.11 | 3.48 ± 1.39 | 3.25 ± 1.15 |
| Marital status |       |        |                              |        |
| Single | 143 (49.8%) | 63 (47.4%) | 80 (51.9%) | 80 (52.2%) | 63 (47%) |
| Married | 143 (49.8%) | 69 (51.9%) | 74 (48.1%) | 72 (47%) | 71 (53%) |
| Divorced | 1 (0.3%) | 1 (0.8%) | 0 (0%) | 1 (0.6%) | 0 (0%) |
| Patient caregiver |       |        |                              |        |
| Him/Herself | 26 (8.7) | 10 (7.2) | 16 (9.9) | 15 (9.3%) | 11 (8%) |
| Spouse | 50 (16.7%) | 26 (20.3%) | 24 (16.4%) | 23 (14.2%) | 27 (19.6%) |
| Children | 31 (10.3%) | 15 (11.7%) | 16 (10.9%) | 15 (9.3%) | 16 (11.6%) |
| Spouse & children | 192 (64%) | 87 (67.9%) | 105 (71.9%) | 108 (66.7%) | 84 (60.9%) |
| Nurse | 1 (0.3%) | 0 (0%) | 1 (0.6%) | 1 (0.6%) | 0 (0%) |
| Smoking status |       |        |                              |        |
| Never smoker | 260 (86.7%) | 117 (84.7%) | 143 (89.3%) | 140 (86.4%) | 120 (88.2%) |
| Former smoker | 30 (10%) | 15 (10.8%) | 15 (9.3%) | 16 (9.9%) | 14 (10.3%) |
| Current smoker | 8 (2.7%) | 6 (4.3%) | 2 (1.2%) | 6 (3.7%) | 2 (1.5%) |
| Smoking duration (years) | 1.15 ± 5.40 | 1.29 ± 5.63 | 1.03 ± 5.21 | 1.04 ± 5.22 | 1.27 ± 5.62 |
| Smoking person in family |       |        |                              |        |
| Yes | 40 (13.3%) | 17 (12.4%) | 23 (14.2%) | 20 (12.4%) | 20 (14.4%) |
| No | 259 (86.3%) | 120 (87.5%) | 139 (85.8%) | 141 (87.6%) | 118 (85.6%) |
| Alcohol history | 11 (3.7%) | 8 (5.8%) | 3 (1.8%) | 8 (4.9%) | 3 (2.1%) |
| Drug abuse history | 4 (1.3%) | 3 (2.1%) | 1 (0.6%) | 3 (1.8%) | 1 (0.7%) |
| Life style habit |       |        |                              |        |
| Sleep change |       |        |                              |        |
| Yes | 152 (50.7%) | 69 (50.7%) | 83 (51.2%) | 69 (42.9%)* | 83 (60.6%) |
| No | 146 (48.7%) | 67 (49.3%) | 79 (48.8%) | 92 (57.1%) | 54 (39.4%) |
| Sleep duration before illness | 7.57 ± 2.07 | 7.49 ± 1.93 | 7.63 ± 2.18 | 7.52 ± 2.27 | 7.62 ± 1.82 |
| Sleep duration after illness | 6.86 ± 2.26 | 6.69 ± 2.46 | 7 ± 2.07 | 6.75 ± 2.22 | 6.98 ± 2.31 |
| Taking sleeping pills before illness | 8 (2.7%) | 5 (3.6%) | 3 (1.8%) | 3 (1.8%) | 5 (3.6%) |
| Facing a stressful event in the last 6 months |       |        |                              |        |
| Yes | 125 (4.7%) | 48 (35.5%)* | 77 (47.5%) | 52 (32.2%)* | 73 (52.8%) |
| No | 174 (58%) | 89 (65%)* | 85 (52.4%) | 109 (67.8%)* | 65 (47.2%) |
| Physiologic condition |       |        |                              |        |
| Breast feeding |       |        |                              |        |
| Yes | 3 (1%) | 2 (1.4%) | 1 (0.6%) | 1 (0.6%) | 2 (1.4%) |
| No | 297 (99%) | 136 (98.6%) | 161 (99.4%) | 161 (99.4%) | 136 (98.6%) |
| Menopausal condition |       |        |                              |        |
| Menopause | 63 (21%) | 26 (18.8%) | 37 (22.8%) | 33 (20.3%) | 30 (21.7%) |
| Non-menopause | 237 (79%) | 112 (81.2%) | 125 (77.2%) | 129 (79.7%) | 106 (78.7%) |
| Responder to the questionnaire |       |        |                              |        |
| Patient | 1 (0.3%) | 0 (0%)* | 1 (0.6%) | 1 (0.6%)* | 0 (0%) |
| Other person | 299 (99.7%) | 138 (100%)* | 161 (99.4%) | 161 (99.4%)* | 138 (100%) |

B.Sc., A Bachelor of Science; M.Sc., A Master of Science; PH.D, Doctor of Philosophy. Qualitative variables are reported as frequency (percent). Quantitative variables are reported as mean ± SD. P-value is reported based on one-way ANOVA test. *P-value is <0.05 and considered as statistically significant.
TABLE 2 | Anthropometric and obesity characteristics of patients with COVID-19.

|                          | Total                  | Recent supplement intake | Long-term supplement intake |
|--------------------------|------------------------|--------------------------|-----------------------------|
|                          | No                     | Yes                      | No                          | Yes                      |
| Height (cm)              | 168 ± 9.33             | 168.68 ± 9.56            | 167.43 ± 9.12               | 166.68 ± 9.37            | 167.22 ± 9.26 |
| Weight (kg)              |                        |                          |                             |                          |               |
| Weight before illness (kg)| 81.84 ± 16.34          | 81.88 ± 17.42            | 81.80 ± 15.41               | 82.24 ± 17.23            | 81.37 ± 15.27 |
| Weight after illness (kg) | 77.75 ± 15.88          | 77.23 ± 16.58            | 78.19 ± 15.30               | 77.94 ± 16.60            | 77.52 ± 15.05 |
| Sudden weight change in the last 6 months | Yes                    | 47 (15.7%)               | 21 (15.4%)                  | 26 (16%)                 | 22 (13.7%)    | 25 (18.1%) |
|                          | No                     | 251 (84.3%)              | 115 (84.6%)                 | 136 (84%)                | 138 (86.3%)   | 113 (81.9%) |
| Sudden weight change in the past year | Yes                    | 110 (36.7%)              | 58 (42.3%)                  | 52 (32%)                 | 72 (44.7%)    | 38 (27.5%) |
|                          | No                     | 189 (63%)                | 79 (57.7%)                  | 110 (68%)                | 89 (55.3%)    | 100 (72.5%) |
| Obesity                  |                        |                          |                             |                          |               |
|                          | Yes                    | 15 (5%)                  | 3 (2.1%) *                  | 12 (7.4%)                | 7 (4.3%)      | 8 (5.7%)    |
|                          | No                     | 285 (95%)                | 135 (97.9%)                 | 150 (92.6%)              | 155 (95.7%)   | 130 (94.3%) |
| BMI (kg/m²)              | 27.48 ± 5.10           | 27.07 ± 5.25             | 27.83 ± 4.95                | 27.34 ± 5.44             | 27.65 ± 4.68  |

BMI, body mass index. Qualitative variables are reported as frequency (percent). Quantitative variables are reported as mean ± SD. P-value is reported based on one-way ANOVA test. *P-value is <0.05 and considered as statistically significant.

the length of hospital stay among Iranian patients with COVID-19. Similarly, people who received supplements in the past year had similar hospitalization duration. Recent supplementation was significantly associated with lower BUN and higher serum 25(OH)D. Furthermore, 25(OH)D serum levels were significantly higher in those who had long-term supplementation during the past year. Moreover, recent supplementation was slightly associated with lower blood creatinine levels. To the best of our knowledge, this is the first study to completely examine the association of recent and long-term consumption of various supplements with different laboratory indicators and the length of hospital stay in patients with COVID-19.

The results of our study showed that people who took supplements modulating the immune system during the year before admission needed significantly less invasive support. This result was consistent with a cohort study that showed that the combination of vitamin D, magnesium, and B12 intake was associated with a reduced need for respiratory support and (or) hospitalization in the ICU (37). The possible mechanism of vitamin D is that it has an effect on NF-κB and reduces pro-inflammatory cytokines and reduces the risk of cytokine storm (38). Magnesium has a positive effect by acting as a cofactor in the synthesis and activation of vitamin D (39). Vitamin B12 also has a positive effect on the gut microbiota and promotes the innate and adaptive immunity of COVID-19 patients (40). Moreover, our study showed that adjuvant supplementation was significantly associated with lower BUN during the 2 months prior to admission. Our results were consistent with the findings of a clinical trial study that showed the effect of omega-3s on BUN reduction in the short term. The mechanism of action of omega-3 is probably by preventing the binding of the SARS-CoV-2 virus to the human ACE2 receptor and activating the host proteases TPRRESS2 and cathepsin L (41). Also, the results of our study were in line with the clinical trial study performed on healthy individuals, which showed a decrease in the ratio of BUN to creatinine after vitamin D supplementation (42). The possible mechanism of this favorable effect of vitamin D supplementation is an alteration in the composition of the microbiota gut, especially increasing Bacteroidetes to Firmicutes ratio (42). Our study findings showed a significant decrease in blood creatinine. This finding was consistent with the systematic review and meta-analysis findings on the use of probiotics and synbiotics that indicated a decrease in blood creatinine levels (43). We observed a significant reduction in CRP, which confirmed the findings of a clinical trial study that showed a significant reduction in inflammatory outcomes following supplementation with vitamins A, B, C, D, and E (44). Our study findings showed a significant decrease in blood LDH levels in supplemented groups. Previous evidence suggests that vitamin D supplementation significantly reduces LDH and CRP serum levels (45). Previous observational studies have mainly focused on the association of specific supplement intake rather than various supplements in COVID-19. A population-based study investigated the association of calcitriol supplementation with mortality in CKD patients and reported a significant association between supplementation and reduction in risk of COVID-19 infection and mortality rate (46). This study has been performed on CKD patients, and it is difficult to extend the results of this study to the general population. Also, some variables may not be considered in the matching process, which is an inherent limitation of this type of study. Furthermore, the study examined only calcitriol, but our study investigated all supplements involved in the immune system (46). A cross-sectional study examined the association of vitamin D supplementation and its outcomes in 19 patients and approached the significance of higher mortality rates (47). However, two of the three groups of participants in the study were either patients with Parkinson’s or Parkinson’s caregivers, which made...
it difficult to extrapolate these results to the general population (47). The study reviewed vitamin D supplementation in the last 3 months, but our study provides data on both recent (2 months ago) and long-term (1 year) intakes of all supplements involved in the immune system (47). Our findings from this study were in line with a clinical trial study, which showed that supplementation did not affect the number of days of hospitalization of COVID-19 patients (48, 49). In contrast, a clinical study demonstrated a favorable association between supplementation and hospital length of stay (50). Naturally, the results obtained from taking a particular supplement may differ from taking different types of supplements and their relationship to the length of hospital stay. Previous studies have examined the association of adjuvant supplementation with clinical symptoms. For instance, recently, a clinical trial showed that high doses of intravenous vitamin C significantly increased the percentage of oxygen saturation and decreased the respiratory rate and the percentage of lung involvement (48). The beneficial effects of vitamin C supplementation are exerted by correcting the disease-induced deficiency, reducing inflammation, increasing interferon production, and supporting the anti-inflammatory action of glucocorticosteroids in acute respiratory infections and critical COVID-19 patients (9). However, some studies did not find a significant effect of vitamin C supplementation on the duration of symptoms and length of hospital stay (51–53). Furthermore, several studies have investigated the association between vitamin D supplementation and clinical symptoms. Vitamin D supplementation improved blood oxygen levels, reduced oxygen requirement, reduced hospital length, and reduced mortality (33). A clinical trial study showed that following vitamin D supplementation, the ratio of arterial oxygen saturation to the inspired fraction of oxygen improved further (54). The vitamin D group also had a shorter average length of stay, less need for ICU transfers, and fewer deaths and readmissions (54). In addition, high-dose vitamin D supplementation normalized serum 25-OH vitamin D levels and was associated with shorter hospital stays, fewer oxygen requirements, and reduced inflammatory markers (33). Although vitamin D’s exact mechanism of action in reducing the risk of infection is yet to be determined, the existing mechanisms are classified into three groups: physical barrier, natural cellular immunity, and adaptive immunity. Vitamin D can play a role in maintaining the physical barrier by improving tight junctions, gap junctions, and junction adhesions (55). Moreover, vitamin D induces antimicrobial peptides, such as human cathelicidin, LL-37, and defensins, thereby enhancing innate cellular immunity (56–58). Finally, vitamin D reduces cytokine storms, which results in enhanced cellular immunity.
TABLE 4 | Clinical and paraclinical parameters in patients with COVID-19 in different supplement intake categories.

|                           | Total            | Recent supplement intake | Long-term supplement intake |
|---------------------------|-------------------|--------------------------|-----------------------------|
|                           | No                | Yes                      | No                          | Yes                          |
| SBP (mmHg)                | 119.51 ± 15.82    | 121.19 ± 15.61           | 117.75 ± 15.99              | 120.22 ± 16.41               | 118.62 ± 15.16               |
| Adjusted                  | 118.33 ± 15.20    | 121.94 ± 13.84           | 113.93 ± 15.86              | 118.88 ± 14.16               | 117.71 ± 16.54               |
| Diastolic BP (mmHg)       | 69.82 ± 19.81     | 72.44 ± 17.67            | 67.31 ± 21.54               | 69.54 ± 21.39                | 70.17 ± 17.93                |
| Adjusted                  | 66.90 ± 23.70     | 73.15 ± 17.43            | 58.65 ± 27.08               | 66.44 ± 25.37                | 65.32 ± 22.27                |
| Headache                  | 60 (20%)          | 25 (18.1%)               | 35 (21.6%)                  | 27 (19.6%)                   | 33 (29.5%)                   |
| Adjusted                  |                   |                          |                             |                             |                             |
| Fever                     | 28 (9.3%)         | 16 (11.5%)               | 12 (7.4%)                   | 17 (12.3%)                   | 11 (9.8%)                    |
| Adjusted                  |                   |                          |                             |                             |                             |
| Duration of fever (days)  | 1.67 ± 7.3        | 2.35 ± 8.75              | 1.06 ± 5.63                 | 2.64 ± 9.21*                 | 0.49 ± 3.54                  |
| Adjusted                  | 1.83 ± 7.65       | 3.07 ± 9.96*             | 0.70 ± 4.41                 | 2.80 ± 9.46*                 | 0.74 ± 4.70                  |
| Respiratory rate (breaths/minute) | 19.3 ± 9.87 | 18.31 ± 5.03 | 20.21 ± 12.74 | 19.51 ± 13.05 | 19.95 ± 2.97 |
| Adjusted                  | 18.54 ± 4.52      | 18.31 ± 5.91*            | 18.75 ± 2.78                | 18.21 ± 5.43*                | 18.91 ± 3.24                 |
| Spo2 (%)                  | 89.52 ± 15.24     | 87.98 ± 18.10            | 90.96 ± 11.91               | 87.44 ± 18.71*               | 92.09 ± 8.78                 |
| Adjusted                  | 89.01 ± 16.43     | 85.89 ± 21.06*           | 91.83 ± 10.03               | 86.77 ± 19.83*               | 91.50 ± 11.20                |
| Ventilator                |                   |                          |                             |                             |                             |
| Yes                       | 105 (35%)         | 58 (48.3%)               | 57 (43.8%)                  | 68 (49.3%)                   | 47 (42%)                     |
| Adjusted                  |                   |                          |                             |                             |                             |
| No                        | 135 (45%)         | 62 (51.7%)               | 73 (56.2%)                  | 70 (50.7%)                   | 65 (58%)                     |
| Adjusted                  |                   |                          |                             |                             |                             |
| Duration of ventilator (days) | 2.69 ± 4.12 | 2.38 ± 3.71 | 2.98 ± 4.47 | 2.78 ± 4.12 | 2.58 ± 4.14 |
| Adjusted                  | 2.61 ± 3.80       | 2.50 ± 3.75*             | 2.71 ± 3.86                 | 2.56 ± 3.88*                 | 2.66 ± 3.72                  |
| Invasive respiratory support | 7 (2.3%)        | 5 (3.6%)                 | 2 (1.2%)                   | 7 (5.1%)*                    | 0 (0%)                       |
| Adjusted                  |                   |                          |                             |                             |                             |
| Non-invasive respiratory support | 104 (34.6%) | 50 (36.2%) | 54 (33.3%) | 58 (42%) | 46 (41.1%) |
| Adjusted                  |                   |                          |                             |                             |                             |
| Ocular congestion         | 8 (2.7%)          | 2 (1.4%)                 | 6 (3.7%)                   | 3 (2.2%)                     | 5 (4.5%)                     |
| Adjusted                  |                   |                          |                             |                             |                             |
| Pulse rate (beats/minute) | 81.91 ± 21.85     | 80.15 ± 24.37            | 83.53 ± 19.19               | 79.79 ± 26.37                | 84.51 ± 14.17                |
| Adjusted                  | 81.98 ± 21.28     | 78.98 ± 25.59*           | 84.68 ± 16.20               | 81.11 ± 25.34*               | 82.94 ± 15.76                |
| Sinusoidal heart rhythm   | 217 (72.3%)       | 99 (71.7%)               | 118 (72.8%)                 | 127 (92.7%)                  | 102 (91.9%)                  |
| Adjusted                  |                   |                          |                             |                             |                             |
| Acute failure syndrome    | 5 (1.7%)          | 2 (1.4%)                 | 3 (1.8%)                   | 3 (2.2%)                     | 2 (1.8%)                     |
| Adjusted                  |                   |                          |                             |                             |                             |

SBP: systolic blood pressure; DBP: diastolic blood pressure; Spo2: saturation of peripheral oxygen. Qualitative variables are reported as frequency (percent). Quantitative variables are reported as mean ± SD. P-value is reported based on one-way ANOVA test. *P-value is <0.05 and considered as statistically significant.

Data are presented as ̅x ± s. Model 1: The P-values were controlled by inpatient, gender, age, history and current onset of diabetes, hypertension, hyperlipidemia, ischemic heart disease, cerebrovascular accident, lung disease, kidney failure, psychiatry disease, obesity, immune deficiency disease, cardiovascular disease, transplant, chronic kidney disease, coronary artery disease, hypothyroid, asthma, congestive heart failure, osteoarthritis, Alzheimer’s disease, rheumatoid arthritis, chronic obstructive pulmonary disease, end-stage renal disease, coronary heart disease, Parkinson’s, hepatitis B, deep vein thrombosis, meningitis and taking hydroxychloroquine, azithromycin, heparin, oseltamivir, Kaletra, ribavirin, famipiravir, remdesivir, azatavirin, intravenous immune globulin, ivemectin, anticoagulants, psychotropic drugs body mass index, hemoglobin, nutrition overall score, existence of respiratory support, fever, blood oxygen level, partial pressure of carbon dioxide, albumin, vitamin D, and c-reactive protein which were included as covariates. P-value is reported based on one-way ANOVA test. *P-value is <0.05 and considered as statistically significant.

(38). However, findings in this regard are inconsistent and some studies have shown that vitamin D supplementation has no effect on ventilator requirement, length of hospital stay, or mortality (59–62). Several studies have examined the association between zinc and clinical parameters. The effect of zinc supplementation on improving survival rate and reducing the length of hospital stay has been shown (63). Similarly, findings from a meta-analysis of 28 clinical trials in patients unlikely to be zinc deficient showed that zinc supplementation orally or intranasal reduced the symptoms of respiratory tract infections and improved the symptoms earlier (64). Likewise, zinc sulfate supplementation, as adjunctive therapy in critically ill patients, reduces 30-day mortality and has a potentially beneficial effect on kidney health (63). Zinc mediates mentioned desired effects by enhancing the anti-infective properties of basophils, eosinophils, and neutrophils (65). Moreover, according to in vitro
research, it may inhibit RNA polymer, which needs further study (66, 67).

Various vitamins are involved in different stages of the immune response by the following possible mechanisms: Vitamin A plays a key role in boosting the function of innate immune cells, such as neutrophils, macrophages, NK cells, and boosting the antibody response (68, 69). Vitamins B6 and B12 also have a positive effect on the adaptive immune response by increasing the number of lymphocytes and enhancing the maturation of lymphocytes (70, 71). Vitamin C stimulates phagocytes and T lymphocytes and protects them against oxidative stress (68, 72). Studies have also shown that vitamins A, B, C, and E prevent cell tissue damage from the virus, and a deficiency in these vitamins can cause NK cells to malfunction (73, 74).

The results of our study showed that people with higher education have significantly more vitamin and mineral supplement intakes in the last 2 months. This is in agreement with Poland cross-sectional study which found that vitamin and mineral supplements, including vitamin D and zinc, were significantly higher in people with a medical degree (75).

Possible confounding variables were adjusted in three phases. One of the factors that may affect the laboratory indices and duration of hospitalization is medication. We examined the interaction of drugs with supplements in such a way that in a separate model, we performed statistical adjustments. If the effect of the interaction of drugs with supplements was significant, then the effect would disappear. In model 1, where the variables of gender, age, history and the current onset of diseases, and history and current medications were adjusted, no significant relationship was observed between supplementation and length of hospital stay. Furthermore, in model 2, no significant association was found following the adjustment of the covariates body mass index, hemoglobin, and nutrition overall score, additionally. Finally, after performing multiple variable adjustments in model 3, we could not find a practical significant favorable relationship between recent and long-term use of supplements with the length of hospital stay in COVID-19 patients. As we know, the nutritional status of the hospitalized person has a significant relationship with the duration of the patient's hospitalization; however, in our study, supplementation has not reduced the number of hospitalization days by improving the nutritional status. Overall, further studies appear to be needed to examine the association of recent and long-term adjuvant supplementation with the length of hospital stay in COVID-19 patients.

The main strength of this study was that it thoroughly investigated the relationship between the intakes of various immune-modulating supplements instead of one particular supplement with the laboratory indices of COVID-19 and the length of hospital stay. Another strength of this study is the complete study of the relationship between the use of supplements in short term and long term with various laboratory indicators of COVID-19 patients. In this cross-sectional study, some limitations should be considered in interpreting our results. According to the cross-sectional design of our study, the cause and effect relationship cannot be deduced from this study. However, it should be noted that a detailed analysis of the findings of the cross-sectional study can be used as a first step to determine the relationship between supplementation and length of hospital stay. Another limitation of this study was that it was conducted in a specific hospital. However, this limitation has been modified due to appropriate random selection and a sample size of 300 people. Furthermore, each questionnaire has its own biases that should be considered. For instance, due to the retrospective nature of our questionnaires and reliance on patients' memory, in some cases, the use of some supplements in the last 2 months and during the year before hospitalization may not be reported accurately. However, as we studied the intake of a large number of supplements, the effect of this error on our results is minimized. Similar studies may show different results due to the time-consuming process of our study and the rapid emergence of new strains of the COVID-19 virus.

**CONCLUSION**

In conclusion, although practically the length of hospital stay was the same in both groups of supplement consumers and others, immune-boosting supplements were associated with improved several laboratory indices. The COVID-19 pandemic constantly raises the question of whether we need to take immune-boosting supplements. Another ambiguity is whether people who

---

**TABLE 5** | Length of hospitalization in different supplement intake categories.

|                  | Total | Recent supplement intake | Total | Long-term supplement intake |
|------------------|-------|--------------------------|-------|-----------------------------|
|                  |       | Yes                      | No    |                             |
|                  |       |                          |       |                             |
| Crude            | 6.93 ± 4.99 | 6.99 ± 4.79             | 6.85 ± 5.22 | 6.93 ± 4.99 |
| Model 1          | 6.42 ± 4.52 | 6.54 ± 4.20             | 6.30 ± 4.84 | 6.42 ± 4.52 |
| Model 2          | 6.67 ± 4.57 | 6.68 ± 4.23             | 6.67 ± 4.91 | 6.67 ± 4.57 |
| Model 3          | 6.53 ± 3.82 | 6.36 ± 3.32*             | 6.71 ± 4.33 | 6.53 ± 3.82 |

Data are presented as mean ± standard deviation. Model 1: The P-values were controlled by gender, age, history and current onset of diabetes, hypertension, hyperlipidemia, ischemic heart disease, cerebrovascular accident, lung disease, kidney failure, psychiatric disease, obesity, immune deficiency disease, cardiovascular disease, transplant, chronic kidney disease, coronary artery disease, hypothyroid, asthma, congestive heart failure, osteoarthritis, Alzheimer’s disease, rheumatoid arthritis, chronic obstructive pulmonary disease, end-stage renal disease, coronary heart disease, Parkinson’s, hepatitis B, deep vein thrombosis, meningitis and taking hydroxychloroquine, azithromycin, heparin, oseltamivir, Kaletra, ribavirin, favipiravir, remdesivir, statin, intravenous immune globulin, keremetc, anticoagulants, and psychotropic drugs which were included as covariates. Model 2: The P-values were controlled by body mass index, hemoglobin, and nutrition overall score which were included as covariates. Model 3: The P-values were controlled by existence of respiratory support, fever and blood oxygen level, partial pressure of carbon dioxide, albumin, vitamin D, and c-reactive protein in addition to the above variables which were included as covariates. P-value is reported based on a one-way ANOVA test. *P-value is <0.05 and considered as statistically significant.
take immune-boosting supplements are less likely to develop the disease, which in our study 54% and 46% of COVID-19 patients had used the supplements in the last 2 months and year, respectively. Apart from the possibility of contracting the disease, there is another question whether patients with a history of supplementation are in a better condition in terms of complications and symptoms, length of hospital stay, laboratory, and paraclinical parameters, which this study can answer all these questions.

However, due to the cross-sectional nature of our study which cannot reveal causal relationships and given that new strains of COVID-19 are developing constantly, further longitudinal studies, concentrating on different types of supplements, seem to be essential.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Materials, further inquiries can be directed to the corresponding author/s.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by Tehran University of Medical Sciences. The studies involving human participants were reviewed and approved by Tehran University of Medical Sciences. The patients/participants provided their written informed consent to participate in this study.

**REFERENCES**

1. Kumar A, Kubota Y, Chernov M, Kasuya H. Potential role of zinc supplementation in prophylaxis and treatment of COVID-19. *Medical Hypotheses*. (2020) 144:109848. doi: 10.1016/j.mehy.2020.109848
2. worldometers. COVID-19 CORONAVIRUS PANDEMIC worldometers: worldometers (2021), 12:52 GMT. Available online at: https://www.worldometers.info/coronavirus/ (accessed September 11, 2021).
3. Centers for Disease Control and Prevention. When You’ve Been Fully Vaccinated October 15, 2021. Available online at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated_archived.html
4. Lange KW, Nakamura Y. Movement and nutrition in COVID-19. *Journal of Disease Prevention and Health Promotion*. (2020) 4. doi: 10.5283/mnhd.33
5. Caccialanza R, Laviano A, Lobascio F, Montagna E, Bruno R, Ludovisi S, et al. Early nutritional supplementation in non-critically ill patients hospitalized for the 2019 novel coronavirus disease (COVID-19): rationale and feasibility of a shared pragmatic protocol. *Nutrition*. (2020) 74:110835. doi: 10.1016/j.nut.2020.110835
6. Carr AC, Maggini S. Vitamin C and immune function. *Nutrients*. (2017) 9:1211. doi: 10.3390/nu9111211
7. Gombart AF, Pierre A, Maggini S, A. review of micronutrients and the immune system–working in harmony to reduce the risk of infection. *Nutrients*. (2020) 12:236. doi: 10.3390/nut12010236
8. Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. *Nutrients*. (2020) 12:988. doi: 10.3390/nut12040988
9. Holford P, Carr AC, Jovic TH, Ali SR, Whitaker IS, Marik PE, et al. Vitamin C—an adjunctive therapy for respiratory infection, sepsis and COVID-19. *Nutrients*. (2020) 12:3760. doi: 10.3390/nut12123760
10. Innes JK, Calder PC. Marine omega-3 (N-3) fatty acids for cardiovascular health: an update for 2020. *Int J Mol Sci*. (2020) 21:1362. doi: 10.3390/ijms21041362
11. Kielszek M, Lipinski B. Selenium supplementation in the prevention of coronavirus infections (COVID-19). *Med Hypotheses*. (2020) 143:109878. doi: 10.1016/j.mehy.2020.109878
12. Martineau AR, Jolliffe DA, Hooper RL, Greenberg L, Aloia JF, Bergman P, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. *BMJ*. (2017) 356:i6583. doi: 10.1136/bmj.i6583
13. Rogero MM, Leão MC, Santana TM, Pimentel M, Carlini GCG, da Silvave TFF, et al. Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19. *Free Radic Biol Med*. (2020) 156:190–9. doi: 10.1016/j.freeradbiomed.2020.07.005
14. Shakoor H, Fehan J, Al Dhaheri AS, Ali HI, Platat C, Ismail LC, et al. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids could they help against COVID-19? *Maturitas*. (2021) 143:1–9. doi: 10.1016/j.maturitas.2020.08.003
15. Siuka D, Pfeifer M, Pinter B. Vitamin D supplementation during the COVID-19 pandemic. *Mayo Clinic proceedings*. (2020) 95:1804–5. doi: 10.1016/j.mayocp.2020.05.036
16. Tang CF, Ding H, Jao RQ, Wu XX, Kong LD. Possibility of magnesium supplementation for supportive treatment in patients with COVID-19. *Eur J Pharmacol*. (2020) 886:173546. doi: 10.1016/j.ejphar.2020.173546
17. Alvarez-Sala J, Alvarez-Mon M. Effect of immunomodulator AM3 on the exacerbations in patients with chronic bronchitis: a systematic review of controlled trials. *Rev Clin Exp*. (2004) 204:666–71. doi: 10.11571/13065976
18. Prieto A, Reyes E, Bernstein ED, Martinez BN, Monserrat J, Izquierdo JL, et al. Defective natural killer and phagocytic activities in chronic obstructive pulmonary disease are restored by glycoporphosphapetial (Inmunoferon). *Am J Resp Crit Care Med*. (2001) 163:1578–83. doi: 10.1164/rccm.163.7.20015
19. Fernández-Lázaro D, Fernandez-Lazaro CI, Mielgo-Ayuso J, Adams DP, Hernández JL, González-Bernal J, et al. Glycophosphopetial AM3 food supplement: a potential adjuvant in the treatment and vaccination of SARS-CoV-2. *Front Immunol*. 2021;12. doi: 10.3389/fimmu.2021.698672

**FUNDING**

This study was supported by the Tehran University of Medical Sciences (grant number: 99-1-212-47266).

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fnut.2022.834826/full#supplementary-material
29. Dhar D, Mohanty A. Gut microbiota and COVID-19 infection. Front Immunol. (2020) 11:1712. doi: 10.3389/fimmu.2020.01712

30. Ali N. Role of vitamin D in preventing of COVID-19 infection, progression and severity. J Infect Public Health. (2020) 13:1373–80. doi: 10.1016/j.jiph.2020.06.023

31. Miryan M, Soleimani D, Dehghani L, Sohrabi K, Khorvash F, Bagheri SE, et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial. J Transl Med. (2021) 19:128. doi: 10.1186/s12976-021-02795-5

32. Moghaddam A, Heller RA, Sun Q, et al. Safety and effectiveness of high-dose zinc and ascorbic acid supplementation vs. usual care on symptom duration in patients with COVID-19: a multicenter, double-blind, randomized controlled trial. JAMA Network Open. (2021) 4:e210373. doi: 10.5812/aapm.25337

33. Ohaegbulam KC, Swalih M, Patel P, Smith MA, Perrin R. Vitamin D and its analogs for COVID-19. J Transl Med. (2020) 18:322. doi: 10.1186/s12976-020-02488-5

34. Abobaker A, Alzwi A, Alraied AHA. Overview of the possible role of vitamin A, vitamin E and selenium in COVID-19. Clin Nutr. (2020) 39:146–153. doi: 10.1016/j.clnu.2020.04.034

35. Chaabouni M, Feki W, Chaabouni K, Kammoun S. Vitamin D and neuroprotective treatment for COVID-19. J Transl Med. (2020) 18:106. doi: 10.1186/s12976-020-02792-8

36. Azar M, Sarkisian E. Food composition table of Iran. National Nutrition and Food Science Research Institute of Shahed Beheshti University. Tehran (1981).

37. Tan CW, Ho LP, Kalimuddin S, Cheng BP, Teh YE, Thien SY, et al. Cohort study to evaluate the effect of vitamin D, magnesium, and vitamin B12 in combination on progression to severe outcomes in older patients with coronavirus (COVID-19). Nutrition. (2020) 79:111017. doi: 10.1016/j.nut.2020.111017

38. Sharifi A, Vahedi H, Nedjat S, Rafii H. Hosseinizadeh-Attar MJ. Effect of single-dose injection of vitamin D on immune cytokines in ulcerative colitis patients: a randomized placebo-controlled trial. APMIS. (2019) 127:681–7. doi: 10.1111/apm.12982

39. Dai Q, Zhu X, Manson JE, Song Y, Li X, Franke AA. Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial. Am J Clin Nutr. (2018) 108:1258–69. doi: 10.1093/ajcn/nqz274

40. Degnan PH, Taga ME, Goodman AL. Vitamin B12 as a modulator of gut microbiota. Curr Metab. (2014) 20:769–78. doi: 10.1016/j.cmet.2014.10.002

41. Doaei S, Gholami S, Rastgoo S, Gholamalizadeh M, Bourbour F, Bagheri SE, et al. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized controlled trial. J Transl Med. (2021) 19:128. doi: 10.1186/s12976-021-02795-5

42. Singh P, Rawat A, Alwakeel M, Sharif E, Al Khodor S. The potential role of vitamin D supplementation as a gut microbiota modifier in healthy individuals. Sci Rep. (2020) 10:1–14. doi: 10.1038/s41598-020-77806-4

43. Abdollahi S, Meshkini F, Clark CC, Heshmati J, Soltani S. The effect of probiotics/synbiotics supplementation on renal and liver biomarkers in patients with type 2 diabetes: a systematic review and meta-analysis of randomized-controlled trials. Br J Nutr. (2021) 1–31. doi: 10.1017/S0007114521003780

44. Beigmohammadi MT, Bitarafan S, Hoseinollahi A, Abdollahi A, Amoozadeh L, Soltani D, et al. The effect of supplementation with vitamins A, B, C, D, and E on disease severity and inflammatory responses in patients with COVID-19: a randomized clinical trial. Trials. (2021) 22:802. doi: 10.1186/s13063-021-05795-4

45. Lakkireddy M, Gadiga SG, Malathi RD, Karla ML, Raju IS, Chinapaka S, et al. Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID-19 disease. Sci Rep. (2021) 11:10641. doi: 10.1038/s41598-021-97181-y

46. Oritrell J, Oliva JC, Subirana I, Casado E, Domínguez D, Alenda P. Association of calcitriol supplementation with reduced covid-19 mortality in patients with chronic kidney disease: a population-based study. Biomedicines. (2021) 9:509. doi: 10.3390/biomedicines9050509

47. Cereda E, Bogoilio L, Lobascio F, Barichella M, Zecchinelli AL, Pezzoli G, et al. Vitamin D supplementation and outcomes in coronavirus disease 2019 (COVID-19) patients from the outbreak area of Lombardy, Italy. Nutrition. (2021) 82:111055. doi: 10.1016/j.nut.2021.111055

48. Tehrani S, Yadegarynia D, Abrishami A, Moradi H, Ghareai B, Rauofi M, et al. An investigation into the effects of intravenous vitamin C on pulmonary CT findings and clinical outcomes of patients with COVID-19 pneumonia a randomized clinical trial. Urol. (2021) 18:6863. doi: 10.22037/uj/v.18/i.6863

49. Murai IH, Fernandes AL, Sales LP, Pinto AJ, Goessler KR, Duran CS, et al. Effect of vitamin D3 supplementation vs. placebo on hospital length of stay and outcomes in severe COVID-19: a multicenter, double-blind, randomized controlled trial. medRxiv. (2020) 325:1053–60. doi: 10.1101/2021.11.16.2232397

50. Sadeghpour A, Alizadehasl A, Yazdankhah N, Moradi H, Haji-Mirzaei VA, et al. The effect of omega-3 fatty acid supplementation on inflammatory markers in patients with COVID-19: a randomized open-label clinical trial. Eur J Med Res. (2021) 26:1–9. doi: 10.1186/s40019-021-00490-1

51. Thomas S, Patel D, Bittel B, Wolski K, Wang Q, Kumar A, et al. Effect of high-dose zinc and ascorbic acid supplementation vs. usual care on symptom length and reduction among ambulatory patients with SARS-CoV-2 infection: the COVID A to Z randomized clinical trial. JAMA Network Open. (2020) 3:e203569. doi: 10.1001/jamanetworkopen.2020.0369

52. Rawat D, Roy A, Maitra S, Gubati A, Khanna P, Raudya DK. Vitamin C and COVID-19 treatment: a systematic review and meta-analysis of randomized controlled trials. Diabetes & metabolic syndrome. Nurs Res Rev. (2021) 102:324. doi: 10.1186/s13073-021-00532-8

53. JamaliMoghadamShahkali S, Sarezaee B, Koolajl S, SeyedAlinaghi S, Zendehdel A, Tabarestani M, et al. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. Cureus. (2020) 12:2098. doi: 10.3390/nu12072098

54. Elamir YM, Amir H, Lim S, Rana YP, Lopez CG, Feliciano NV, et al. A randomized pilot study using 490 calcitriol in hospitalized COVID-19 patients. Bone. (2022) 154:116175. doi: 10.1016/j.bone.2021.116175
55. Schwalfenberg GK. A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. *Mol Nutr Food Res.* (2011) 55:96–108. doi: 10.1002/mnfr.201000174

56. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. *Science.* (2006) 311:1770–3. doi: 10.1126/science.1123933

57. Adams JS, Ren S, Liu PT, Chun RF, Lagishetty V, Gombart AF, et al. Vitamin D-directed Rhoestatic regulation of monocyte antibacterial responses. *J Immunol.* (2009) 182:4289–95. doi: 10.4049/jimmunol.0803736

58. Laaksi I. Vitamin D and respiratory infection in adults. *Proced Nutr Soc.* (2012) 71:90–7. doi: 10.1017/S0029665111003351

59. da Rocha AP, Atallah AN, Aldrighi JM, Pires ALR, dos Santos Puga ME, Pinto ACPN. Insufficient evidence for vitamin D use in COVID-19: a rapid systematic review. *Int J Clin Pract.* (2020) 74:e14649. doi: 10.1111/ijcp.14649

60. Güven M, Gültekin H. The effect of high-dose parenteral vitamin D3 on COVID-19-related in hospital mortality in COVID-19 patients during intensive care unit admission: an observational cohort study. *Eur J Clin Nutr.* (2021) 75:1383–8. doi: 10.1038/s41430-021-00984-5

61. Rawat D, Roy A, Maitra S, Shankar V, Khanna P, Baidya DK. Vitamin D supplementation and COVID-19 treatment: a systematic review and meta-analysis. *Diabetes & metabolic syndrome.* (2021) 15:102189. doi: 10.1016/j.dsx.2021.102189

62. Arroyo-Díaz JA, Julve J, Vlacho B, Corcoy R, Ponte P, Román E, et al. Previous vitamin D supplementation and morbidity and mortality outcomes in people hospitalized for COVID19: a cross-sectional study. *Front Pub Health.* (2021) 9:8347. doi: 10.3389/fpubh.2021.758347

63. Al Sulaiman K, Al Juhani O, Al Shaya AI, Kharbosh A, Kensara R, Al Guwairy A, et al. Evaluation of zinc sulfate as an adjunctive therapy in COVID-19 critically ill patients: a two center propensity-score matched study. (2021) 54:96–108. doi: 10.1002/mnfr.201000174

64. Hunter J, Arentz S, Goldenberg J, Yang G, Beardsley J, Myers SP, et al. Zinc for hospitalized for COVID19: a cross-sectional study. *J. Antiviral activity of the zinc ionophores pyrithione and hinokitiol blocking of picornavirus infections.* *J Virol.* (2009) 83:58. doi: 10.1128/JVI.01336-08

65. Gammoh NZ, Rink L. Zinc in infection and inflammation. *Nutrients.* (2017) 9:624. doi: 10.3390/nu9060624

66. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathogens.* (2010) 6:e1001076. doi: 10.1371/journal.ppat.1001176

67. Krenn BM, Gaudernak E, Holzer B, Lanke K, Van Kuppeveld FJ, Seipelt J. Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections. *J Virol.* (2009) 83:58. doi: 10.1128/JVI.01336-08

68. Maggini S, Beveridge S, Sorbara P, Senatore G. Feeding the immune system: the role of micronutrients in restoring resistance to infections. *CAB Rev: Perspect Agric, Veter Sci, Nutri Nat Res.* (2008) 3:1–21. doi: 10.1079/PAYSNNR20083098

69. Maggini S, Wintergerst ES, Beveridge S, Hornig DH. Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses. *Br J Nutri.* (2007) 98:529–35. doi: 10.1017/S0007114507832971

70. Wishart K. Increased micronutrient requirements during physiologically demanding situations: review of the current evidence. *Vitamin Miner.* (2017) 6:1–16. doi: 10.4172/2376-1318.1000166

71. Cheng C, Chang S-J, Lee B, Lin K, Huang Y. Vitamin B6 supplementation increases immune responses in critically ill patients. *Eur J Clin Nutr.* (2006) 60:1207–13. doi: 10.1038/sj.ejcn.1602439

72. Anderson R, Oosthuizen R, Maritz R, Theron A, Van Rensburg A. The effects of increasing weekly doses of ascorbate on certain cellular and humoral immune functions in normal volunteers. *Am J Clin Nutr.* (1980) 33:71–6. doi: 10.1093/ajcn/33.1.71

73. Hemila H, Chalker E. Vitamin C can shorten the length of stay in the ICU: a meta-analysis. *Nutrients.* (2019) 11:708. doi: 10.3390/nu11040708

74. Erickson KL, Medina EA, Hubbard NE. Micronutrients and innate immunity. *J Infect Dis.* (2000) 182(Supplement_1):S5–S10 doi: 10.1086/315922

75. Puścian-Jakubik A, Bielecka J, Grabia M, Mielech A, Markiewicz-Zułowska R, Mielcarek K, et al. Consumption of food supplements during the three COVID-19 waves in Poland—focus on Zinc and Vitamin D. *Nutrients.* (2021) 13:3361. doi: 10.3390/nu13103361

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Hashemi, Montazer, Salehi and Azadbakht. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.